Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis Delta and 96 weeks of posttreatment follow-up - Wedemeyer, H; Aleman, S; Blank, A; Andreone, P; Bogomolov, P; Chulanov, V; Mamonova, N; Geyvandova, N; Morozov, V; Sagalova, O; Stepanova, T; Berger, A; Ciesek, S; Deterding, K; Lichtman, A; Manuilov, D; Mercier, R-C; Arterburn, S; Christian-Cox, F; Tseng, S; Osinusi, A; Sculze zur Wiesch, J; Cornberg, M; Zeuzem, S; Brunetto, M; Lampertico, P (Zeitschrift für Gastroenterologie, 2025)